Przejdź do zawartości
Merck

Ibuprofen arginate retains eNOS substrate activity and reverses endothelial dysfunction: implications for the COX-2/ADMA axis.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2016-09-08)
Nicholas S Kirkby, Abel Tesfai, Blerina Ahmetaj-Shala, Hime H Gashaw, Walkyria Sampaio, Gisele Etelvino, Nádia Miricéia Leão, Robson A Santos, Jane A Mitchell
ABSTRAKT

Nonsteroidal antiinflammatory drugs, including ibuprofen, are among the most commonly used medications and produce their antiinflammatory effects by blocking cyclooxygenase (COX)-2. Their use is associated with increased risk of heart attacks caused by blocking COX-2 in the vasculature and/or kidney, with our recent work implicating the endogenous NOS inhibitor asymmetric dimethylarginine (ADMA), a cardiotoxic hormone whose effects can be prevented by l-arginine. The ibuprofen salt ibuprofen arginate (Spididol) was created to increase solubility but we suggest that it could also augment the NO pathway through codelivery of arginine. Here we investigated the idea that ibuprofen arginate can act to simultaneously inhibit COX-2 and preserve the NO pathway. Ibuprofen arginate functioned similarly to ibuprofen sodium for inhibition of mouse/human COX-2, but only ibuprofen arginate served as a substrate for NOS. Ibuprofen arginate but not ibuprofen sodium also reversed the inhibitory effects of ADMA and N

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
NG,NG-Dimethylarginine dihydrochloride
Sigma-Aldrich
Ibuprofen Arginate, ≥98% (HPLC)